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Background: Impact of colchicine on recurrence of acute pericarditis & primary prevention of post-cardiotomy syndrome (PPS) is not well defined. 
We conducted a meta-analysis of all randomized clinical trials (RCTs) to assess the impact of colchicine therapy on rate of PPS and recurrent 
pericarditis.
Methods: A comprehensive literature search [PubMed] identified 5 RCTs (3 RCTs evaluating acute or recurrent pericarditis & 2 RCTs evaluating 
PPS). Primary clinical endpoint included rate of recurrent pericarditis or incidence of PPS. Review Manager 5.1 (Cochrane Collaboration) was used to 
conduct meta-analysis. Odds ratios (OR) & 95% confidence interval (CI) were calculated using Random Effects Model.
Results: Of the 795 patients analyzed, 389 received colchicine & 406 received conventional therapy. Majority of patients in the colchicine (61%) 
and conventional therapy (56%) arms were males (P= 0.94), & had comparable age(59.8 & 60.7 yrs, respectively, P= 0.99). At a total follow-
up of 1,216 patient-years, colchicine use was associated with significant reduction in primary clinical end-point (incidence of PPS or recurrent 
pericarditis): 15.7 vs. 36.0%; OR = 0.25, 95% CI 0.13 - 0.47; NNT = 4.9 (Figure-1). The rates of adverse events related to therapy were similar in the 
colchicine (7.4%) and conventional therapy (5.9%) arms (P = 0.71).
Conclusion: Colchicine use was associated with a 75% relative risk reduction (NNT = 4.9) in recurrent pericarditis or the incidence of PPS 
compared with conventional therapy.
 
